Latham Advises on Financing for Hanger and Numotion’s Combination

Cheplapharm, advised by Latham & Watkins, will acquire 20 medicines and three manufacturing sites from Sanofi. Sanofi will gain a 26.4% stake in Cheplapharm, with the deal expected to close in Q3 2027. Cheplapharm anticipates becoming the fifth-largest German pharma company upon completion.

Realty Income and KKR formed a joint venture to own European net-lease real estate assets. KKR will invest €528 million for a 49% stake, with Realty Income retaining 51%. The deal is expected to close by September 30, 2026. Latham & Watkins advised KKR on the transaction.

GSK agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for up to $750M. The asset targets multiple myeloma, with phase I trials expected in 2027. GSK aims to improve tolerability and efficacy. Latham & Watkins advised on the deal.

Ares Alternative Credit committed over $2 billion to Eni for a long-term partnership on upstream infrastructure, advised by Latham & Watkins. The deal aims to boost Eni's cash generation and growth. Ares focuses on asset-based finance beyond traditional markets.

Beta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.

BKV Corporation (NYSE: BKV) priced a $575M offering of 1.625% convertible senior notes due 2031, upsized from $400M. Latham & Watkins advised the initial purchasers.